Hoy Group

Research Groups: Prof Jennifer Hoy

Photo: Prof Jennifer HoyPhoto

Prof Jennifer Hoy (pictured above)

Overview:

Professor Hoy is the Director of the Victorian HIV Service, Infectious Diseases Unit, The Alfred Hospital/Monash University. Her research interests include:

  • HIV and its complications including cardiovascular disease and bone disease;

  • Effects of HIV and antiretroviral treatment on bone disease, and co-chairs the Bone Mineral Density sub-study of the International START study.

Research Areas:

HIV and Bone Disease

HIV-infected persons have lower bone mineral density (BMD) and more fractures than the general population of similar age.  Both HIV-infection and antiretroviral treatment (ART) for HIV contribute to BMD loss, along with traditional risk factors; the relative contributions of HIV and ART are unknown.

Current collaborative studies underway:

  • The effect of HIV alone and introduction of ART is being evaluated in 400 patients in the START study (START BMD substudy). Recruitment is complete worldwide, and follow-up continues.

  • It is known that all ART drugs can increase BMD loss in HIV patients, but tenofovir appears to have a significantly greater effect. In patients with low BMD, it is unknown whether switching the tenofovir for another ART drug or treatment with a bisphosphonate is the more effective and safe option. A randomised trial is underway to determine this.

The following laboratory and clinical research projects are aimed  at understanding HIV latency in vitro and in vivo:

HIV and Bone Disease

HIV and Cardiovascular Diseases

Cardiovascular disease has now become one of the major causes of morbidity and mortality in people living with HIV, who have a 2-fold increased risk when compared with the general population.

This elevated risk is likely due to a complex interplay between the increased incidence of traditional cardiac risk factors, the effects of ARV medications and the pro-inflammatory actions of HIV itself.

A number of projects are being undertaken to better understand the contributions of lipid abnormalities, chronic inflammation and platelet function in the observed increased risk of atherosclerosis and clinical CVD events.

The following laboratory and clinical research projects are aimed  at understanding HIV latency in vitro and in vivo:

HIV and Cardiovascular Disease

Contact details:

Prof Jennifer Hoy
Lab Head

Jennifer.Hoy@monash.edu

Dr Janine Trevillyan
PhD Student

Janine.trevillyan@monash.edu